Page 190 - Haematologica Vol. 110 - January 2025

LETTER TO THE EDITOR
manuscript. SE designed this sub-study, analyzed data, made the table and wrote the first draft of the manuscript. IS and GL analyzed the data, made the figures and the table. CD, MV, IT, GJ, MH participated in designing the trial and participated in analyzing data. All authors critically reviewed, edited and approved the manuscript.
Funding
The study was funded by the Gothenburg Medical Society (GLS-
References
1. Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.
2. Blimark CH, Vangsted AJ, Klausen TW, et al. Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries. Eur J Haematol. 2022;108(2):99-108.
3. Backhaus E, Berg S, Andersson R, et al. Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors. BMC Infect Dis. 2016;16:367.
4. Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59(8):1066-1073.
5. Thompson MA, Boccadoro M, Leleu X, et al. Rates of influenza and pneumococcal vaccination and correlation with survival in multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2023;23(3):e171-e181.
6. Hoornaert E, Dachy F, Hansenne A, et al. COVID-19: impact of vaccination in myeloma patients. Ann Hematol. 2022;101(7):1607-1608.
7. Renaud L, Schraen S, Fouquet G, et al. Response to pneumococcal vaccination in multiple myeloma. Cancer Med. 2019;8(8):3822-3830.
8. Mustafa SS, Shah D, Bress J, Jamshed S. Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls. Hum Vaccin Immunother. 2019;15(2):452-454.
98874) and The Operational Health Care Committee, Region Vastra Gotaland, Sweden (VGFOUREG-982351).
Data-sharing statement
For original data, please contact the corresponding author. As per Swedish law, individual participant data will not be shared.
9. Noonan K, Rudraraju L, Ferguson A, et al. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res. 2012;18(5):1426-1434.
10. Frerichs KA, Bosman PWC, van Velzen JF, et al. Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients. Haematologica. 2020;105(6):e302-e306.
11. Wiedmeier-Nutor JE, Iqbal M, Rosenthal AC, et al. Response to COVID-19 vaccination post-CAR T therapy in patients with non-Hodgkin lymphoma and multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23(6):456-462.
12. Ludwig H, Boccadoro M, Moreau P, et al. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2021;35(1):31-44.
13. Raje NS, Anaissie E, Kumar SK, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9(2):e143-e161.
14. Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107-113.
15. Teh BW, Worth LJ, Harrison SJ, Thursky KA, Slavin MA. Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital. Support Care Cancer. 2015;23(7):1901-1906.
Haematologica | 110 January 2025
182